TSHR; | |
MGAM; | |
TDP1; BLM; HSD17B1; AOX1; | |
MAPK1; ABL1; EGFR; | |
CA12; CA7; CA4; | |
ESR1; ESR2; | |
ESRRB; ESRRA; | |
MAOA; ALDH2; | |
HIF1A; TP53; NFKB1; | |
ABCG2; | |
SLCO1B3; SLCO1B1; | |
LMNA; NPC1; RAB9A; THPO; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0005496; steroid binding | 5.389E-09 | 5.867E-05 | ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.232E-08 | 5.975E-04 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.917E-07 | 1.784E-03 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 6.702E-07 | 1.824E-03 | ABCG2, ABL1, CA12, CA7, EGFR, ESR1, HIF1A, MAPK1, TP53 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 8.994E-07 | 1.940E-03 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.403E-06 | 1.971E-03 | ABL1, BLM, EGFR, ESR1, MAPK1, NFKB1, NPC1 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.687E-06 | 2.018E-03 | ABL1, CA7, EGFR, HIF1A, MAPK1, NPC1 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.854E-06 | 2.018E-03 | CA12, CA4, CA7 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.659E-06 | 2.412E-03 | ESR1, ESR2 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.822E-06 | 2.458E-03 | CYP1A2, CYP2C19, CYP2C9, ESR1, HSD17B1, NPC1 |
BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 3.070E-06 | 2.571E-03 | ABL1, BLM, EGFR, MAPK1, NFKB1, TP53, TSHR |
BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 4.619E-06 | 3.612E-03 | EGFR, ESRRB, HIF1A |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.645E-06 | 3.612E-03 | BLM, CA12, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, TP53 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.383E-06 | 3.786E-03 | CYP1A2, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.156E-06 | 4.062E-03 | AOX1, CYP1A2, CYP2C19, CYP2C9, TBXAS1 |
BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 7.968E-06 | 4.690E-03 | ABL1, HIF1A |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.279E-05 | 6.964E-03 | CA4, EGFR, SLCO1B1, SLCO1B3, TSHR |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.592E-05 | 7.704E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.592E-05 | 7.704E-03 | CYP1A2, CYP2C9 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.799E-05 | 7.994E-03 | CYP1A2, EGFR, MAPK1 |
MF | GO:0003824; catalytic activity | GO:0004497; monooxygenase activity | 1.776E-05 | 7.994E-03 | CYP1A2, CYP2C19, CYP2C9, TBXAS1 |
BP | GO:0065007; biological regulation | GO:1900274; regulation of phospholipase C activity | 2.841E-05 | 9.820E-03 | ABL1, EGFR, ESR1 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.841E-05 | 9.820E-03 | CA12, CA4, CA7 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.901E-08 | 1.296E-05 | CYP2C9; MAOA; CYP1A2; AOX1; CYP2C19 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.736E-07 | 3.884E-05 | ALDH2; MAOA; CYP1A2; AOX1 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.628E-06 | 1.264E-04 | MAPK1; TP53; EGFR; NFKB1 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 5.144E-06 | 1.274E-04 | MAPK1; ESR1; NFKB1; ESR2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.854E-06 | 1.264E-04 | MAPK1; TP53; HIF1A; EGFR |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.436E-06 | 1.274E-04 | ABL1; MAPK1; TP53; NFKB1 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.198E-05 | 2.408E-04 | MAPK1; TP53; EGFR; NFKB1 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.652E-05 | 2.710E-04 | MAPK1; TP53; HIF1A; ESR1; EGFR |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.448E-05 | 3.755E-04 | ABL1; MAPK1; HIF1A; TP53; EGFR; NFKB1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.826E-05 | 2.722E-04 | MAPK1; ESR1; EGFR; ESR2 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.492E-06 | 1.264E-04 | CA12; CA4; CA7 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.135E-05 | 2.918E-04 | MAPK1; HIF1A; EGFR; NFKB1 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.969E-05 | 3.746E-04 | CYP2C9; MAOA; MAPK1; CYP2C19 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.644E-05 | 3.755E-04 | MAPK1; TP53; ESR1; HIF1A |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.892E-05 | 3.755E-04 | ABL1; MAPK1; TP53; NFKB1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.102E-05 | 6.130E-04 | LMNA; MAPK1; TP53; NFKB1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 9.981E-05 | 7.216E-04 | CYP2C9; MGAM; ALDH2; MAOA; HSD17B1; TBXAS1; CYP1A2; AOX1; CYP2C19 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.817E-05 | 5.300E-04 | MAPK1; TP53; EGFR; NFKB1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.322E-05 | 2.408E-04 | CYP2C9; CYP1A2; CYP2C19 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.012E-04 | 7.216E-04 | ABL1; MAPK1; TP53; EGFR; NFKB1 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.806E-05 | 3.755E-04 | MAPK1; TP53; EGFR |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 9.736E-05 | 7.216E-04 | MAPK1; TP53; EGFR |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 7.796E-05 | 6.393E-04 | MAPK1; TP53; EGFR |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.519E-04 | 9.228E-04 | MAPK1; TP53; EGFR |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 4.528E-04 | 2.321E-03 | ABL1; MAPK1; EGFR; NFKB1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.320E-04 | 9.018E-04 | CYP2C9; TBXAS1; CYP2C19 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.975E-04 | 1.117E-03 | MAPK1; TP53; EGFR |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.519E-04 | 9.228E-04 | CYP2C9; CYP1A2; AOX1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 7.009E-04 | 3.284E-03 | MAPK1; TP53; EGFR; NFKB1 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 3.600E-04 | 1.904E-03 | ABL1; MAPK1; EGFR |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 5.574E-04 | 2.770E-03 | MAPK1; HIF1A; EGFR |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.519E-04 | 9.228E-04 | ABL1; MAPK1; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.975E-04 | 1.117E-03 | SLCO1B1; SLCO1B3; ABCG2 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.024E-04 | 1.653E-03 | CYP2C9; CYP1A2; CYP2C19 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.048E-03 | 7.997E-03 | MAPK1; TP53; EGFR; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 1.320E-03 | 5.553E-03 | RAB9A; TP53; NFKB1 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 9.202E-04 | 4.079E-03 | MAPK1; TP53; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.619E-03 | 6.474E-03 | MAPK1; TP53; NFKB1 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.892E-03 | 1.302E-02 | MAPK1; NFKB1; TSHR |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 4.229E-03 | 1.360E-02 | MAPK1; TP53; NFKB1 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.747E-03 | 1.302E-02 | MAPK1; NFKB1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 6.072E-03 | 1.747E-02 | MAPK1; NFKB1 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.135E-02 | 2.778E-02 | MAPK1; NFKB1 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 4.143E-03 | 1.359E-02 | MAPK1; HIF1A |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 9.294E-03 | 2.382E-02 | MAPK1; EGFR |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 4.991E-03 | 1.544E-02 | MAPK1; HIF1A |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 6.072E-03 | 1.747E-02 | MAPK1; NFKB1 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 9.891E-03 | 2.458E-02 | TP53; NFKB1 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.335E-02 | 3.084E-02 | MAPK1; NFKB1 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.200E-02 | 2.852E-02 | MAPK1; NFKB1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.244E-02 | 2.915E-02 | MAPK1; NFKB1 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.624E-02 | 3.650E-02 | TBXAS1; MAPK1 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 4.417E-03 | 1.393E-02 | MAPK1; TP53 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 5.290E-03 | 1.606E-02 | EGFR; NFKB1 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.200E-02 | 2.852E-02 | MAPK1; NFKB1 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 8.337E-03 | 2.205E-02 | TP53; NFKB1 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.747E-03 | 1.302E-02 | MAPK1; NFKB1 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 8.714E-03 | 2.268E-02 | MAPK1; EGFR |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.525E-02 | 3.474E-02 | MAPK1; NFKB1 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 6.235E-03 | 1.763E-02 | MAPK1; EGFR |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.072E-03 | 1.747E-02 | CYP2C9; CYP1A2 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 8.337E-03 | 2.205E-02 | MAPK1; NFKB1 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.884E-02 | 4.066E-02 | MAPK1; NFKB1 |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.217E-02 | 4.603E-02 | MAPK1; EGFR |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.160E-02 | 4.542E-02 | ESRRB; MAPK1 |
hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 2.672E-03 | 1.019E-02 | ALDH2; AOX1 |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.911E-02 | 4.070E-02 | MAPK1; EGFR |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.675E-02 | 3.712E-02 | ABL1; TP53 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.752E-02 | 3.832E-02 | ABL1; MAPK1 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.783E-03 | 1.037E-02 | MAOA; NFKB1 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 6.399E-03 | 1.779E-02 | MAPK1; NFKB1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.877E-03 | 1.302E-02 | HSD17B1; CYP1A2 |
hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 2.896E-03 | 1.055E-02 | ALDH2; MAOA |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 9.801E-04 | 4.230E-03 | MAPK1; TP53 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 8.490E-04 | 3.868E-03 | MAPK1; EGFR |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.428E-03 | 5.854E-03 | MAOA; AOX1 |
hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 6.696E-04 | 3.230E-03 | ALDH2; MAOA |
hsa00750 | Vitamin B6 metabolism_Homo sapiens_hsa00750 | 9.563E-03 | 2.413E-02 | AOX1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.975E-03 | 2.180E-02 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; TBXAS1; MGAM |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1 |
C00-D49: Neoplasms | Leukemia | C90-C95 | ABL1; ESR1 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ALDH2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR |
C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA |
A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MAPK1; ABL1; EGFR |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | ABL1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR |
C00-D49: Neoplasms | Melanoma | C43 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
C00-D49: Neoplasms | Breast cancer | C50 | EGFR; EGFR; EGFR; ESR1; ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
NA: NA | Menopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | MGAM |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA |
A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | MGAM |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; MAPK1; ABL1; NFKB1; EGFR; ESR1; ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
C00-D49: Neoplasms | Prostate cancer | C61 | ABL1; EGFR; ESR1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; ESRRA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; ALDH2 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; EGFR; EGFR |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | ABL1 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |